Sponsor Pipeline

Hangzhou Converd Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
2
Recruiting
1
Disease Areas
Active Trials by Phase
Phase 2
1
Phase 1
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07006077 Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced… Advanced Pancreatic Cancer Recruiting
Phase 1
NCT05914376 Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in… Advanced Solid Tumors Active, Not Recruiting
Not specified
NCT07185243 A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1… Advanced Solid Tumors Recruiting
Disease Areas
Pancreatic Cancer (1)
Get alerts when Hangzhou Converd Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free